Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

316 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Brain structure and function: a multidisciplinary pipeline to study hominoid brain evolution.
Friederici AD, Wittig RM, Anwander A, Eichner C, Gräßle T, Jäger C, Kirilina E, Lipp I, Düx A, Edwards LJ, Girard-Buttoz C, Jauch A, Kopp KS, Paquette M, Pine KJ, Unwin S, Haun DBM, Leendertz FH, McElreath R, Morawski M, Gunz P, Weiskopf N, Crockford C; EBC Consortium. Friederici AD, et al. Among authors: jauch a. Front Integr Neurosci. 2024 Jan 8;17:1299087. doi: 10.3389/fnint.2023.1299087. eCollection 2023. Front Integr Neurosci. 2024. PMID: 38260006 Free PMC article.
Artificial intelligence-based, volumetric assessment of the bone marrow metabolic activity in [18F]FDG PET/CT predicts survival in multiple myeloma.
Sachpekidis C, Enqvist O, Ulén J, Kopp-Schneider A, Pan L, Mai EK, Hajiyianni M, Merz M, Raab MS, Jauch A, Goldschmidt H, Edenbrandt L, Dimitrakopoulou-Strauss A. Sachpekidis C, et al. Among authors: jauch a. Eur J Nucl Med Mol Imaging. 2024 Mar 8. doi: 10.1007/s00259-024-06668-z. Online ahead of print. Eur J Nucl Med Mol Imaging. 2024. PMID: 38456971
Post-transplant Inflammatory Bowel Disease Associated with Donor-Derived TIM-3 Deficiency.
Baldrich A, Althaus D, Menter T, Hirsiger JR, Köppen J, Hupfer R, Juskevicius D, Konantz M, Bosch A, Drexler B, Gerull S, Ghosh A, Meyer BJ, Jauch A, Pini K, Poletti F, Berkemeier CM, Heijnen I, Panne I, Cavelti-Weder C, Niess JH, Dixon K, Daikeler T, Hartmann K, Hess C, Halter J, Passweg J, Navarini AA, Yamamoto H, Berger CT, Recher M, Hruz P. Baldrich A, et al. Among authors: jauch a. J Clin Immunol. 2024 Feb 16;44(3):63. doi: 10.1007/s10875-024-01667-z. J Clin Immunol. 2024. PMID: 38363399 Free PMC article.
Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial.
Mai EK, Goldschmid H, Miah K, Bertsch U, Besemer B, Hänel M, Krzykalla J, Fenk R, Schlenzka J, Munder M, Dürig J, Blau IW, Huhn S, Hose D, Jauch A, Kunz C, Mann C, Weinhold N, Scheid C, Schroers R, von Metzler I, Schieferdecker A, Thomalla J, Reimer P, Mahlberg R, Graeven U, Kremers S, Martens UM, Kunz C, Hensel M, Benner A, Seidel-Glätzer A, Weisel KC, Raab MS, Salwender HJ; German-speaking Myeloma Multicenter Group (GMMG) HD6 investigators. Mai EK, et al. Among authors: jauch a. Lancet Haematol. 2024 Feb;11(2):e101-e113. doi: 10.1016/S2352-3026(23)00366-6. Lancet Haematol. 2024. PMID: 38302221 Free article. Clinical Trial.
Chromosome 8p engineering reveals increased metastatic potential targetable by patient-specific synthetic lethality in liver cancer.
Huth T, Dreher EC, Lemke S, Fritzsche S, Sugiyanto RN, Castven D, Ibberson D, Sticht C, Eiteneuer E, Jauch A, Pusch S, Albrecht T, Goeppert B, Candia J, Wang XW, Ji J, Marquardt JU, Nahnsen S, Schirmacher P, Roessler S. Huth T, et al. Among authors: jauch a. Sci Adv. 2023 Dec 22;9(51):eadh1442. doi: 10.1126/sciadv.adh1442. Epub 2023 Dec 22. Sci Adv. 2023. PMID: 38134284 Free PMC article.
RNA-sequencing based first choice of treatment and determination of risk in multiple myeloma.
Emde-Rajaratnam M, Beck S, Benes V, Salwender H, Bertsch U, Scheid C, Hänel M, Weisel K, Hielscher T, Raab MS, Goldschmidt H, Jauch A, Maes K, De Bruyne E, Menu E, De Veirman K, Moreaux J, Vanderkerken K, Seckinger A, Hose D. Emde-Rajaratnam M, et al. Among authors: jauch a. Front Immunol. 2023 Nov 15;14:1286700. doi: 10.3389/fimmu.2023.1286700. eCollection 2023. Front Immunol. 2023. PMID: 38035078 Free PMC article.
Daratumumab, Bortezomib, and Dexamethasone for Treatment of Patients with Relapsed or Refractory Multiple Myeloma and Severe Renal Impairment: Results from the Phase 2 GMMG-DANTE Trial.
Leypoldt LB, Gavriatopoulou M, Besemer B, Salwender H, Raab MS, Nogai A, Khandanpour C, Runde V, Jauch A, Zago M, Martus P, Goldschmidt H, Bokemeyer C, Dimopoulos MA, Weisel KC. Leypoldt LB, et al. Among authors: jauch a. Cancers (Basel). 2023 Sep 21;15(18):4667. doi: 10.3390/cancers15184667. Cancers (Basel). 2023. PMID: 37760637 Free PMC article.
316 results